+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Zika Virus Infection - Pipeline Insight, 2021

  • ID: 5310609
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Emergent BioSolutions
  • Emergex vaccines
  • GeneOne Life Science
  • Hercules Pharmaceuticals
  • Inovio Pharmaceuticals
  • MORE
This “Zika virus infection - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Zika virus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Zika virus infection Understanding

Zika virus infection: Overview

Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes, which bite during the day. Symptoms are generally mild and include fever, rash, conjunctivitis, muscle and joint pain, malaise or headache. Symptoms typically last for 2-7 days. Most people with Zika virus infection do not develop symptoms. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. An increased risk of neurologic complications is associated with Zika virus infection in adults and children, including Guillain-Barré syndrome, neuropathy and myelitis.

"Zika virus infection- Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Zika virus infection pipeline landscape is provided which includes the disease overview and Zika virus infection treatment guidelines. The assessment part of the report embraces, in depth Zika virus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Zika virus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Zika virus infection R&D. The therapies under development are focused on novel approaches to treat/improve Zika virus infection.

Zika virus infection Emerging Drugs Chapters

This segment of the Zika virus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Zika virus infection Emerging Drugs

GLS-5700: GeneOne Life Science

GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika virus infection and is currently in Phase I stage of development.

ZIKV-IG: Emergent BioSolutions

ZIKV-IG is being developed for Zika virus infection by Emergent Biosolutions and acts as immunostimulants. It is currently in Phase I stage of development.

Zika virus infection: Therapeutic Assessment

This segment of the report provides insights about the different Zika virus infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Zika virus infection

There are approx. 15+ key companies which are developing the therapies for Zika virus infection. The companies which have their Zika virus infection drug candidates in the most advanced stage, i.e. Phase I include, GeneOne Life Science.

Phases

This report covers around 15+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Zika virus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Zika virus infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Zika virus infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Zika virus infection drugs.

Zika virus infection Report Insights
  • Zika virus infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Zika virus infection Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Zika virus infection drugs?
  • How many Zika virus infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Zika virus infection?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Zika virus infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Zika virus infection and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • GeneOne Life Science
  • Emergent BioSolutions
  • Inovio Pharmaceuticals
  • Hercules Pharmaceuticals
  • Emergex vaccines
Key Products
  • GLS-5700
  • ZIKV-IG
  • INO A002
  • HP 163
Research Programme: Zika
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Emergent BioSolutions
  • Emergex vaccines
  • GeneOne Life Science
  • Hercules Pharmaceuticals
  • Inovio Pharmaceuticals
  • MORE
Introduction

Executive Summary

Zika virus infection: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Zika virus infection- Analytical Perspective

In-depth Commercial Assessment
  • Zika virus infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Zika virus infection Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
GLS-5700: GeneOne Life Science
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Research programme: Zika: Emergex vaccines
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Zika virus infection Key Companies

Zika virus infection Key Products

Zika virus infection- Unmet Needs

Zika virus infection- Market Drivers and Barriers

Zika virus infection- Future Perspectives and Conclusion

Zika virus infection Analyst Views

Zika virus infection Key Companies

Appendix

List of Tables
Table 1 Total Products for Zika virus infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Zika virus infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • GeneOne Life Science
  • Emergent BioSolutions
  • Inovio Pharmaceuticals
  • Hercules Pharmaceuticals
  • Emergex vaccines
Note: Product cover images may vary from those shown
Adroll
adroll